Genotype and X-chromosome inactivation are associated with disease severity in females with X-linked Alport syndrome.

COL4A5 X-chromosome inactivation X-linked Alport syndrome female genotype

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
12 Aug 2024
Historique:
medline: 13 8 2024
pubmed: 13 8 2024
entrez: 12 8 2024
Statut: aheadofprint

Résumé

Male patients with X-linked Alport syndrome (XLAS) generally develop end-stage kidney disease in early or middle adulthood and show distinct genotype-phenotype correlations. Female patients, however, show various phenotypes ranging from asymptomatic to severe with no genotype-phenotype correlations. However, the factors affecting the severity of XLAS in female patients are unclear. Since X-chromosome inactivation (XCI) affects the severity of certain female X-linked diseases, we investigated whether genotype and XCI were associated with XLAS severity in female patients in a large Japanese cohort. Among 139 female patients with genetically diagnosed XLAS at our institution, we conducted XCI analysis on peripheral blood leukocytes using the human androgen receptor assay method and analyzed two cohorts. In 74 adult female patients, we evaluated the correlation between kidney function (creatinine-estimated glomerular filtration rate [Cr-eGFR] optimized for Japanese individuals) and genotype/XCI using multivariable linear regression analysis, and in 65 pediatric female patients, we evaluated the correlation between kidney function (Cr-eGFR optimized for Japanese individuals) and genotype/XCI using multivariable linear regression analysis. We also investigated the correlation between the development of proteinuria (urine protein-to-creatinine ratio above normal for the patient's age) and genotype/XCI using multivariable Cox proportional hazard analysis. In adult female patients, XCI pattern was significantly associated with Cr-eGFR (regression coefficient estimate = -0.53, P = 0.004), whereas genotype was not (P = 0.892). In pediatric female patients, both genotype and XCI pattern were significant independent risk factors for the development of proteinuria (hazard ratio [HR], 3.702; 95% confidence interval [CI], 1.681-8.150; P = 0.001 and HR, 1.043; 95% CI, 1.061-1.070; P = 0.001, respectively), whereas both genotype and XCI pattern were not associated with Cr-eGFR (P = 0.20, P = 0.67, respectively). Genotype and XCI are factors associated with the severity in females with XLAS.

Sections du résumé

BACKGROUND AND HYPOTHESIS OBJECTIVE
Male patients with X-linked Alport syndrome (XLAS) generally develop end-stage kidney disease in early or middle adulthood and show distinct genotype-phenotype correlations. Female patients, however, show various phenotypes ranging from asymptomatic to severe with no genotype-phenotype correlations. However, the factors affecting the severity of XLAS in female patients are unclear. Since X-chromosome inactivation (XCI) affects the severity of certain female X-linked diseases, we investigated whether genotype and XCI were associated with XLAS severity in female patients in a large Japanese cohort.
METHODS METHODS
Among 139 female patients with genetically diagnosed XLAS at our institution, we conducted XCI analysis on peripheral blood leukocytes using the human androgen receptor assay method and analyzed two cohorts. In 74 adult female patients, we evaluated the correlation between kidney function (creatinine-estimated glomerular filtration rate [Cr-eGFR] optimized for Japanese individuals) and genotype/XCI using multivariable linear regression analysis, and in 65 pediatric female patients, we evaluated the correlation between kidney function (Cr-eGFR optimized for Japanese individuals) and genotype/XCI using multivariable linear regression analysis. We also investigated the correlation between the development of proteinuria (urine protein-to-creatinine ratio above normal for the patient's age) and genotype/XCI using multivariable Cox proportional hazard analysis.
RESULTS RESULTS
In adult female patients, XCI pattern was significantly associated with Cr-eGFR (regression coefficient estimate = -0.53, P = 0.004), whereas genotype was not (P = 0.892). In pediatric female patients, both genotype and XCI pattern were significant independent risk factors for the development of proteinuria (hazard ratio [HR], 3.702; 95% confidence interval [CI], 1.681-8.150; P = 0.001 and HR, 1.043; 95% CI, 1.061-1.070; P = 0.001, respectively), whereas both genotype and XCI pattern were not associated with Cr-eGFR (P = 0.20, P = 0.67, respectively).
CONCLUSION CONCLUSIONS
Genotype and XCI are factors associated with the severity in females with XLAS.

Identifiants

pubmed: 39134512
pii: 7732058
doi: 10.1093/ndt/gfae182
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

Auteurs

Ryota Suzuki (R)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Nana Sakakibara (N)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Sae Murakami (S)

Clinical and Translational Research Center, Kobe University Hospital.

Yuta Ichikawa (Y)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Hideaki Kitakado (H)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Chika Ueda (C)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Yu Tanaka (Y)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Eri Okada (E)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Atsushi Kondo (A)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Yuya Aoto (Y)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Shinya Ishiko (S)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Shingo Ishimori (S)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

China Nagano (C)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Tomohiko Yamamura (T)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Tomoko Horinouchi (T)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Takayuki Okamoto (T)

Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Kandai Nozu (K)

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Classifications MeSH